XML 29 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive (Loss) Gain
Other Accumulated Deficit
Balance, beginning of period (in shares) at Dec. 31, 2021   68,435,257      
Balance, beginning of period at Dec. 31, 2021 $ 553,642 $ 7 $ 1,411,827 $ (493) $ (857,699)
Statement of Stockholders' Equity (Deficit)          
Exercise of stock options (in shares)   12,573      
Exercise of stock options 218   218    
Stock-based compensation expense 11,431   11,431    
Vesting of restricted common stock awards (in shares)   154,834      
Vesting of restricted common stock awards 0        
Unrealized gain (loss) on marketable debt securities (2,016)     (2,016)  
Net loss (50,515)       (50,515)
Balance, end of period (in shares) at Mar. 31, 2022   68,602,664      
Balance, end of period at Mar. 31, 2022 512,760 $ 7 1,423,476 (2,509) (908,214)
Balance, beginning of period (in shares) at Dec. 31, 2021   68,435,257      
Balance, beginning of period at Dec. 31, 2021 553,642 $ 7 1,411,827 (493) (857,699)
Statement of Stockholders' Equity (Deficit)          
Unrealized gain (loss) on marketable debt securities (3,798)        
Net loss (159,694)        
Balance, end of period (in shares) at Sep. 30, 2022   68,761,729      
Balance, end of period at Sep. 30, 2022 414,745 $ 7 1,436,422 (4,291) (1,017,393)
Balance, beginning of period (in shares) at Mar. 31, 2022   68,602,664      
Balance, beginning of period at Mar. 31, 2022 512,760 $ 7 1,423,476 (2,509) (908,214)
Statement of Stockholders' Equity (Deficit)          
Exercise of stock options (in shares)   20      
Exercise of stock options 0        
Stock-based compensation expense 6,618   6,618    
Vesting of restricted common stock awards (in shares)   77,884      
Vesting of restricted common stock awards 0        
Issuance of common stock under employee stock purchase plan (in shares)   37,866      
Issuance of common stock under employee stock purchase plan 367   367    
Unrealized gain (loss) on marketable debt securities (878)     (878)  
Net loss (53,453)       (53,453)
Balance, end of period (in shares) at Jun. 30, 2022   68,718,434      
Balance, end of period at Jun. 30, 2022 465,414 $ 7 1,430,461 (3,387) (961,667)
Statement of Stockholders' Equity (Deficit)          
Exercise of stock options (in shares)   4,976      
Exercise of stock options 80   80    
Stock-based compensation expense 5,881   5,881    
Vesting of restricted common stock awards (in shares)   38,319      
Vesting of restricted common stock awards 0        
Unrealized gain (loss) on marketable debt securities (904)     (904)  
Net loss (55,726)       (55,726)
Balance, end of period (in shares) at Sep. 30, 2022   68,761,729      
Balance, end of period at Sep. 30, 2022 414,745 $ 7 1,436,422 (4,291) (1,017,393)
Balance, beginning of period (in shares) at Dec. 31, 2022   68,847,382      
Balance, beginning of period at Dec. 31, 2022 360,680 $ 7 1,442,405 (3,601) (1,078,131)
Statement of Stockholders' Equity (Deficit)          
Stock-based compensation expense 4,507   4,507    
Vesting of restricted common stock awards (in shares)   146,209      
Vesting of restricted common stock awards 0        
Unrealized gain (loss) on marketable debt securities 1,322     1,322  
Net loss (49,036)       (49,036)
Balance, end of period (in shares) at Mar. 31, 2023   68,993,591      
Balance, end of period at Mar. 31, 2023 317,473 $ 7 1,446,912 (2,279) (1,127,167)
Balance, beginning of period (in shares) at Dec. 31, 2022   68,847,382      
Balance, beginning of period at Dec. 31, 2022 360,680 $ 7 1,442,405 (3,601) (1,078,131)
Statement of Stockholders' Equity (Deficit)          
Unrealized gain (loss) on marketable debt securities 2,149        
Net loss (134,345)        
Balance, end of period (in shares) at Sep. 30, 2023   81,668,796      
Balance, end of period at Sep. 30, 2023 360,462 $ 8 1,574,382 (1,452) (1,212,476)
Balance, beginning of period (in shares) at Mar. 31, 2023   68,993,591      
Balance, beginning of period at Mar. 31, 2023 317,473 $ 7 1,446,912 (2,279) (1,127,167)
Statement of Stockholders' Equity (Deficit)          
Issuance of common stock from public offering, net commissions, underwriting discounts and offering costs (in shares)   12,500,000      
Issuance of common stock from public offering, net commissions, underwriting discounts and offering costs 117,079 $ 1 117,078    
Exercise of stock options (in shares)   3,122      
Exercise of stock options 11   11    
Stock-based compensation expense 5,215   5,215    
Vesting of restricted common stock awards (in shares)   64,492      
Vesting of restricted common stock awards 0        
Issuance of common stock under employee stock purchase plan (in shares)   55,704      
Issuance of common stock under employee stock purchase plan 435   435    
Unrealized gain (loss) on marketable debt securities (6)     (6)  
Net loss (40,290)       (40,290)
Balance, end of period (in shares) at Jun. 30, 2023   81,616,909      
Balance, end of period at Jun. 30, 2023 399,917 $ 8 1,569,651 (2,285) (1,167,457)
Statement of Stockholders' Equity (Deficit)          
Stock-based compensation expense 4,731   4,731    
Vesting of restricted common stock awards (in shares)   51,887      
Vesting of restricted common stock awards 0        
Unrealized gain (loss) on marketable debt securities 833     833  
Net loss (45,019)       (45,019)
Balance, end of period (in shares) at Sep. 30, 2023   81,668,796      
Balance, end of period at Sep. 30, 2023 $ 360,462 $ 8 $ 1,574,382 $ (1,452) $ (1,212,476)